Cargando…
P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430576/ http://dx.doi.org/10.1097/01.HS9.0000846136.56070.c0 |
| _version_ | 1784779809667153920 |
|---|---|
| author | Yenerel, M. N. Sicre de Fontbrune, F. Piatek, C. Sahin, F. Füreder, W. Ogawa, M. Tomazos, I. Doll, H. Ozol-Godfrey, A. Sierra, J. R. Szer, J. |
| author_facet | Yenerel, M. N. Sicre de Fontbrune, F. Piatek, C. Sahin, F. Füreder, W. Ogawa, M. Tomazos, I. Doll, H. Ozol-Godfrey, A. Sierra, J. R. Szer, J. |
| author_sort | Yenerel, M. N. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430576 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94305762022-08-31 P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB Yenerel, M. N. Sicre de Fontbrune, F. Piatek, C. Sahin, F. Füreder, W. Ogawa, M. Tomazos, I. Doll, H. Ozol-Godfrey, A. Sierra, J. R. Szer, J. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430576/ http://dx.doi.org/10.1097/01.HS9.0000846136.56070.c0 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Yenerel, M. N. Sicre de Fontbrune, F. Piatek, C. Sahin, F. Füreder, W. Ogawa, M. Tomazos, I. Doll, H. Ozol-Godfrey, A. Sierra, J. R. Szer, J. P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB |
| title | P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB |
| title_full | P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB |
| title_fullStr | P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB |
| title_full_unstemmed | P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB |
| title_short | P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB |
| title_sort | p813: efficacy, treatment administration satisfaction and safety of subcutaneous ravulizumab through 1 year in patients with paroxysmal nocturnal hemoglobinuria who received prior intravenous eculizumab |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430576/ http://dx.doi.org/10.1097/01.HS9.0000846136.56070.c0 |
| work_keys_str_mv | AT yenerelmn p813efficacytreatmentadministrationsatisfactionandsafetyofsubcutaneousravulizumabthrough1yearinpatientswithparoxysmalnocturnalhemoglobinuriawhoreceivedpriorintravenouseculizumab AT sicredefontbrunef p813efficacytreatmentadministrationsatisfactionandsafetyofsubcutaneousravulizumabthrough1yearinpatientswithparoxysmalnocturnalhemoglobinuriawhoreceivedpriorintravenouseculizumab AT piatekc p813efficacytreatmentadministrationsatisfactionandsafetyofsubcutaneousravulizumabthrough1yearinpatientswithparoxysmalnocturnalhemoglobinuriawhoreceivedpriorintravenouseculizumab AT sahinf p813efficacytreatmentadministrationsatisfactionandsafetyofsubcutaneousravulizumabthrough1yearinpatientswithparoxysmalnocturnalhemoglobinuriawhoreceivedpriorintravenouseculizumab AT furederw p813efficacytreatmentadministrationsatisfactionandsafetyofsubcutaneousravulizumabthrough1yearinpatientswithparoxysmalnocturnalhemoglobinuriawhoreceivedpriorintravenouseculizumab AT ogawam p813efficacytreatmentadministrationsatisfactionandsafetyofsubcutaneousravulizumabthrough1yearinpatientswithparoxysmalnocturnalhemoglobinuriawhoreceivedpriorintravenouseculizumab AT tomazosi p813efficacytreatmentadministrationsatisfactionandsafetyofsubcutaneousravulizumabthrough1yearinpatientswithparoxysmalnocturnalhemoglobinuriawhoreceivedpriorintravenouseculizumab AT dollh p813efficacytreatmentadministrationsatisfactionandsafetyofsubcutaneousravulizumabthrough1yearinpatientswithparoxysmalnocturnalhemoglobinuriawhoreceivedpriorintravenouseculizumab AT ozolgodfreya p813efficacytreatmentadministrationsatisfactionandsafetyofsubcutaneousravulizumabthrough1yearinpatientswithparoxysmalnocturnalhemoglobinuriawhoreceivedpriorintravenouseculizumab AT sierrajr p813efficacytreatmentadministrationsatisfactionandsafetyofsubcutaneousravulizumabthrough1yearinpatientswithparoxysmalnocturnalhemoglobinuriawhoreceivedpriorintravenouseculizumab AT szerj p813efficacytreatmentadministrationsatisfactionandsafetyofsubcutaneousravulizumabthrough1yearinpatientswithparoxysmalnocturnalhemoglobinuriawhoreceivedpriorintravenouseculizumab |